Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
38.93
+2.32 (6.34%)
At close: Sep 26, 2025, 4:00 PM EDT
38.95
+0.02 (0.05%)
After-hours: Sep 26, 2025, 7:39 PM EDT
Agios Pharmaceuticals Employees
As of December 31, 2024, Agios Pharmaceuticals had 488 total employees, including 486 full-time and 2 part-time employees. The number of employees increased by 102 or 26.42% compared to the previous year.
Employees
488
Change (1Y)
102
Growth (1Y)
26.42%
Revenue / Employee
$83,760
Profits / Employee
$1,332,137
Market Cap
2.26B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AGIO News
- 9 days ago - AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 12 days ago - AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
- 19 days ago - Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive - Seeking Alpha
- 23 days ago - Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha
- 23 days ago - FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Benzinga
- 23 days ago - Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia - GlobeNewsWire
- 7 weeks ago - Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - GlobeNewsWire
- 2 months ago - Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript - Seeking Alpha